findmyKOL
Clinical trialNCT00430846CompletedPhase 1Interventional

Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies

SponsorSeagen Inc.Enrollment45Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama at Birmingham

    Birmingham, Alabama, United States

  • Washington University

    St Louis, Missouri, United States

  • Weill Cornell Medical College

    New York, New York, United States

  • University of Texas/md Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Nov 2006
Primary completion
31 Jul 2009
Completion
31 Jul 2009
Last update posted
18 Dec 2014
Registered enrollment
45
Registry id
NCT00430846
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.